Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Blended vision of refractive rotational asymmetric intraocular lens (IOL) Oculentis Mplus X MF30 and Oculentis Mplus MF20

Search Title by author or title

Session Details

Session Title: Pseudophakic IOLs: Multifocal II

Session Date/Time: Sunday 08/10/2017 | 10:30-12:30

Paper Time: 11:56

Venue: Room 2.1

First Author: : A.Kok Khiang MALAYSIA

Co Author(s): :    E. Shakira Amran                    

Abstract Details


To evaluate the bilateral visual outcomes (distance, intermediate and near) in 28 patients with bilateral implantation with Oculentis Mplus X MF30 and Oculentis Mplus MF20, 1 month after cataract surgery.


Setting/Venue: VISTA Eye Specialist, Malaysia


This study comprised patients who had successful bilateral cataract extraction with Oculentis Mplus X MF30 implanted on the non-dominant eye and Oculentis Mplus MF20 on the dominant eye (n=28). The surgery on each eye had been done on consecutive days. Parameters analysed included binocular uncorrected vision distance, intermediate and near acuities, spectacle independence, subjective visual symptoms and patient satisfaction.


At post-op 1 month, the mean bilateral UCDVA was 0.05±0.06 logMAR with 92% (26 eyes) achieving 20/25 (6/7.5) or better (p<0.003), mean bilateral UCIVA was 0.05±0.05 logMAR with 100% (28 eyes) achieving 20/25 or better (p>0.001) and mean bilateral UCNVA was 0.06±0.03 logMAR with 100% (28eyes) achieving J2 (N5) or better (p>0.005) with Lentis Mplus X MF30 and Lentis Mplus MF20 in 28 patients. Most of the patients did not wear glasses for daily activities and reported high satisfaction especially less glares and no haloes in overall performance.


Bilateral implantation of Oculentis Mplus X MF30 and Oculentis Mplus MF20 provide excellent distance, intermediate and near vision. The combination of both refractive rotational asymmetric model give excellent performance with fast adaptation and high satisfactory among patients.

Financial Disclosure:


Back to previous